Cargando…

An explorative analysis of the prognostic value of lactate dehydrogenase for survival and the chemotherapeutic response in patients with advanced triple-negative breast cancer

Serum lactate dehydrogenase (LDH) level is predictive of prognosis in various malignancies. Nevertheless, the association between the prognosis of patients with advanced triple-negative breast cancer (TNBC) and LDH is not well understood. This explorative and retrospective study was conducted to cla...

Descripción completa

Detalles Bibliográficos
Autores principales:	Jia, Zhenya, Zhang, Jian, Wang, Zhonghua, Wang, Biyun, Wang, Leiping, Cao, Jun, Tao, Zhonghua, Hu, Xichun
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Impact Journals LLC 2018
Materias:	Research Paper
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5828224/ https://www.ncbi.nlm.nih.gov/pubmed/29535837 http://dx.doi.org/10.18632/oncotarget.24246

Ejemplares similares

Overall survival of cancer patients with serum lactate dehydrogenase greater than 1000 IU/L
por: Liu, Rujiao, et al.
Publicado: (2016)

Phase 1b clinical trial of pucotenlimab (HX008), a novel anti-PD-1 monoclonal antibody, combined with gemcitabine and cisplatin in the first-line treatment of metastatic triple-negative breast cancer
por: Cao, Jun, et al.
Publicado: (2022)

Chemotherapy of metastatic triple negative breast cancer: Experience of using platinum-based chemotherapy
por: Zhang, Jian, et al.
Publicado: (2015)

Whether low-dose metronomic oral cyclophosphamide improves the response to docetaxel in first-line treatment of non-triple-negative metastatic breast cancer
por: Zhang, Jian, et al.
Publicado: (2017)

Exosomal annexin A6 induces gemcitabine resistance by inhibiting ubiquitination and degradation of EGFR in triple-negative breast cancer
por: Li, Ting, et al.
Publicado: (2021)

Cisplatin shows greater efficacy than gemcitabine when combined with nab-paclitaxel in metastatic triple-negative breast cancer
por: Li, Yi, et al.
Publicado: (2019)

Incidence, pattern and prognosis of brain metastases in patients with metastatic triple negative breast cancer
por: Jin, Jia, et al.
Publicado: (2018)

GSTT1, GSTP1, and GSTM1 genetic variants are associated with survival in previously untreated metastatic breast cancer
por: Zhang, Jian, et al.
Publicado: (2017)

Mammary adipocytes protect triple-negative breast cancer cells from ferroptosis
por: Xie, Yizhao, et al.
Publicado: (2022)

Clinical Outcomes of 130 Patients with Hormone Receptor-Positive and Human Epidermal Growth Factor Receptor 2-Negative Metastatic Breast Cancer Treated with Palbociclib plus Endocrine Therapy and Subsequent Therapy: A Real-World Single-Center Retrospective Study in China
por: Liu, Chang, et al.
Publicado: (2020)

Analysis of clinical features, genomic landscapes and survival outcomes in HER2-low breast cancer
por: Jin, Juan, et al.
Publicado: (2023)

Optimal duration of prior endocrine therapy predicts the efficacy of Fulvestrant in a real‐world study for patients with hormone receptor‐positive and HER2‐negative advanced breast cancer
por: Zhao, Yannan, et al.
Publicado: (2020)

Phase II Study of Pseudomonas aeruginosa-Mannose-Sensitive Hemagglutinin in Combination with Capecitabine for Her-2–Negative Metastatic Breast Cancer Pretreated with Anthracycline and Taxane
por: Lv, Fangfang, et al.
Publicado: (2015)

A randomized phase II study of aromatase inhibitors plus metformin in pre-treated postmenopausal patients with hormone receptor positive metastatic breast cancer
por: Zhao, Yannan, et al.
Publicado: (2017)

Multicenter phase II study of Apatinib in non-triple-negative metastatic breast cancer
por: Hu, Xichun, et al.
Publicado: (2014)

Dalpiciclib Combined With Pyrotinib and Letrozole in Women With HER2-Positive, Hormone Receptor-Positive Metastatic Breast Cancer (LORDSHIPS): A Phase Ib Study
por: Zhang, Jian, et al.
Publicado: (2022)

Heterogeneity of targeted lung lesion predicts platinum-based first-line therapy outcomes and overall survival for metastatic triple-negative breast cancer patients with lung metastasis: a “PET biopsy” method
por: Xie, Yizhao, et al.
Publicado: (2019)

Real-World Data of Pyrotinib-Based Therapy in Metastatic HER2-Positive Breast Cancer: Promising Efficacy in Lapatinib-Treated Patients and in Brain Metastasis
por: Lin, Ying, et al.
Publicado: (2020)

Comparison of two regimens of weekly paclitaxel plus gemcitabine in patients with metastatic breast cancer: propensity score–matched analysis of real-world data
por: Gong, Chengcheng, et al.
Publicado: (2022)

Prognostic and predictive value of clinical and biochemical factors in breast cancer patients with bone metastases receiving "metronomic" zoledronic acid
por: Zhao, Xinmin, et al.
Publicado: (2011)

Caveolin-1 expression predicts efficacy of weekly nab-paclitaxel plus gemcitabine for metastatic breast cancer in the phase II clinical trial
por: Zhao, Yannan, et al.
Publicado: (2018)

Bevacizumab in Combination with Modified FOLFOX6 in Heavily Pretreated Patients with HER2/Neu-Negative Metastatic Breast Cancer: A Phase II Clinical Trial
por: Li, Ting, et al.
Publicado: (2015)

Efficacy and safety of mitoxantrone hydrochloride liposome injection in Chinese patients with advanced breast cancer: a randomized, open-label, active-controlled, single-center, phase II clinical trial
por: Wang, Leiping, et al.
Publicado: (2021)

miR-331-3p Suppresses Cell Proliferation in TNBC Cells by Downregulating NRP2
por: Zhao, Mingchuan, et al.
Publicado: (2020)

PI3K pathway activation results in low efficacy of both trastuzumab and lapatinib
por: Wang, Leiping, et al.
Publicado: (2011)

Temporal Heterogeneity of HER2 Expression and Spatial Heterogeneity of (18)F-FDG Uptake Predicts Treatment Outcome of Pyrotinib in Patients with HER2-Positive Metastatic Breast Cancer
por: Gong, Chengcheng, et al.
Publicado: (2022)

Identification of DDIT4 as a potential prognostic marker associated with chemotherapeutic and immunotherapeutic response in triple-negative breast cancer
por: Chen, Xuanzhao, et al.
Publicado: (2023)

Pre-treatment serum alkaline phosphatase and lactate dehydrogenase as prognostic factors in triple negative breast cancer
por: Chen, Bo, et al.
Publicado: (2016)

Efficacy and safety of everolimus in Chinese metastatic HR positive, HER2 negative breast cancer patients: a real-world retrospective study
por: Gong, Chengcheng, et al.
Publicado: (2017)

Phase II trail of nab-paclitaxel in metastatic breast cancer patients with visceral metastases
por: Xie, Yizhao, et al.
Publicado: (2021)

PDGFD induces ibrutinib resistance of diffuse large B-cell lymphoma through activation of EGFR
por: Jin, Jia, et al.
Publicado: (2020)

Prognostic value of preoperative serum lactate dehydrogenase levels for resectable gastric cancer and prognostic nomograms
por: Wang, Zi-Xian, et al.
Publicado: (2016)

Chromatin Remodelling Molecule ARID1A Determines Metastatic Heterogeneity in Triple-Negative Breast Cancer by Competitively Binding to YAP
por: Wang, Ye, et al.
Publicado: (2023)

LINC01605 promotes aerobic glycolysis through lactate dehydrogenase A in triple‐negative breast cancer
por: Wang, Wei, et al.
Publicado: (2022)

The prognostic value of lactate dehydrogenase levels in colorectal cancer: a meta-analysis
por: Li, Guanghua, et al.
Publicado: (2016)

Prognostic Value of Lactate Dehydrogenase in Patients with Hepatocellular Carcinoma: A Meta-Analysis
por: Kong, Weihao, et al.
Publicado: (2018)

The prognostic and predictive potential of Ki-67 in triple-negative breast cancer
por: Zhu, Xiuzhi, et al.
Publicado: (2020)

Prognostic value of D-lactate dehydrogenase in patients with clear cell renal cell carcinoma
por: Wang, Yue, et al.
Publicado: (2018)

Vimentin Promotes the Aggressiveness of Triple Negative Breast Cancer Cells Surviving Chemotherapeutic Treatment
por: Winter, Marie, et al.
Publicado: (2021)

A risk stratification model for predicting brain metastasis and brain screening benefit in patients with metastatic triple‐negative breast cancer
por: Lin, Mingxi, et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_vml8hrm5c9j9t8bbi6fb6cpsr5